Use

Resolution ctDx Lung™ is a non‑invasive liquid biopsy assay performed on a blood (cfDNA) sample from patients with non‑small cell lung cancer (NSCLC) to detect actionable somatic mutations, indels, fusions, and copy number variants across 22 genes. It is intended to inform treatment decisions by identifying driver alterations linked to FDA‑approved therapies or clinical trial agents, especially when tissue biopsy is limited or unavailable. Clinical data report detection of somatic mutations in 64% of patients, with high concordance rates (90–96%) compared to tissue NGS and 97% response in patients receiving plasma‑directed therapy. (Labcorp Oncology page; Resolution Bioscience)